Gut Liver.  2018 Jul;12(4):393-401. 10.5009/gnl17384.

Continuous Use of Thienopyridine May Be as Safe as Low-Dose Aspirin in Endoscopic Resection of Gastric Tumors

• Oh S
• Kim SG
• Kim J
• Choi JM
• Lim JH
• Yang HJ
• Park JY
• Han SJ
• Kim JL
• Chung H
• Jung HC

• KMID: 2417305
• DOI: http://doi.org/10.5009/gnl17384

Abstract

BACKGROUND/AIMS
Current guidelines recommend withholding antiplatelets for 5-7 days before high-risk endoscopic procedures. We investigated whether this reduces post-endoscopic submucosal dissection (ESD) bleeding.
METHODS
Gastric ESD cases with antiplatelets were retorospectively reviewed. Withholding antiplatelets for 5-7 days before ESD was defined as cessation and 0-4 days as continuation. The rate and risk of post-ESD bleeding according to the types and cessation of antiplatelets were assessed.
RESULTS
Among the 215 patients (117 adenoma and 98 early gastric cancer), 161 patients were on single (94 aspirin, 56 thienopyridine, and 11 other agents), 51 on dual, and 3 on triple antiplatelets. Post-ESD bleeding rates were 12.8% in aspirin users, 3.6% in thienopyridine, 27.5% in dual, 33.3% in triple therapy, and 9.7% in the cessation and 15.0% in the continuation group. Multiple antiplatelets (odds ratio [OR], 2.41; 95% confidence interval [CI], 1.01 to 5.76) and specimen size ≥ 5.5 cm (OR, 2.84; 95% CI, 1.04 to 7.73) were the risk of bleeding, while continuation of thienopyridine (OR, 0.23; 95% CI, 0.05 to 1.09) and antiplatelets (OR, 1.83; 95% CI, 0.68 to 4.94) did not increase the risk of bleeding.
CONCLUSIONS
Continuing thienopyridine and aspirin did not increase the risk of post-ESD. Multiple antiplatelet therapy and a large specimen size were independent risk factors of post-ESD bleeding.

Keyword

Antiplatelet; Aspirin; Thienopyridine; Endoscopic submucosal dissection; Post-endoscopic submucosal dissection bleeding

MeSH Terms

Adenoma
Aspirin*
Hemorrhage
Humans
Risk Factors
Aspirin